Lataa...
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective...
Tallennettuna:
| Julkaisussa: | Genes (Basel) |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8228461/ https://ncbi.nlm.nih.gov/pubmed/34200676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/genes12060899 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|